Acute Myeloid Leukemia in Children in Resource Limited Setting: Experience from a Tertiary Paediatric Oncology Center of Eastern India

Dipshikha Maiti; Apurba Ghosh

Dipshikha Maiti Assistant Professor, Department of Paediatrics, Institute of Child Health, Kolkata, West Bengal, India.
Apurba Ghosh Executive Director, Institute of Child Health, Kolkata, West Bengal, India

Keywords: Paediatric Acute Myeloid Leukaemia, Survival, Outcome, Daunorubicin

Abstract

Introduction: Acute myeloid leukaemia (AML) is a difficult disease to treat in resource-limited settings. Data from India is limited to identifying trends or shortcomings and planning remedial strategies.
Objective: To analyse the clinical profile and outcome in children with AML treated with daunorubicin-based induction protocol in a Paediatric oncology centre.
Methodology: This study looks at the outcomes of 27 patients with paediatric AML treated at our centre from January 2018 and June 2020. They were treated with daunorubicin-based induction followed by consolidation with high-dose cytarabine.
Results: The complete remission rate in this study is 66.7%. Toxicity related deaths were seen in deaths were seen in 25.9% of cases. The relapse rate is 22.2%. Event-free survival (EFS) in the cohort at 2.5
years was 51.8%.
Conclusion: This study demonstrates good EFS with the use of the daunorubicin-based protocol in resource-limited settings as compared to previously reported studies. The toxicity-related deaths especially in induction can be further reduced if we can ensure early referral of patients and prompt treatment.

How to cite this article:
Maiti D, Ghosh A. Acute Myeloid Leukemia in
Children in Resource-Limited Setting: Experience
from a Tertiary Paediatric Oncology Center of
Eastern India. Int J Preven Curat Comm Med.
2024;10(3&4):3-6.

DOI: https://doi.org/10.24321/2454.325X.202406

References

Kulkarni KP, Marwaha RK. Childhood acute myeloid leukemia: an Indian perspective. Pediatr Hematol

Oncol. 2011;28(4):257-68. [PubMed] [Google Scholar]

Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jurgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12):2030-42. [PubMed] [Google Scholar]

Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ; Children’s Cancer Group. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19(12):2054-62. [PubMed] [Google Scholar]